TY  - JOUR
TT  - The influence of obesity on the recurrence of cancer in HER-2 positive breast cancer patients related to adjuvant trastuzumab treatment
AU  - Gököz Doğu, Gamze
AU  - Kargı, Aysegül
AU  - Yaren, Arzu
AU  - Yapar Taşköylü, Burcu
AU  - Demiray, A. Gökcen
PY  - 2013
DA  - April
JF  - Pamukkale Medical Journal
JO  - Pam Tıp Derg
PB  - Pamukkale Üniversitesi
WT  - DergiPark
SN  - 1308-0865
SP  - 5
EP  - 11
IS  - 1
KW  - Adjuvan tedavi
KW  - HER-2
KW  - meme kanseri
KW  - trastuzumab
KW  - obezite
N2  - Purpose: Trastuzumab, a humanized monoclonal antibody, was shown to prolong survival in female HER-2 positive early stage breast cancer patients. We examined whether obesity had an influence on the recurrences of HER-2 positive patients, as related to adjuvant trastuzumab treatment, retrospectively. Materials and methods: Among HER-2 positive 170 patients, 129 had accessible data, and with 114, recorded weight / height measurements were statistically analyzed. Results: Of these, the body mass index (BMI) was <30 kg/m2 in 68 (60%), and ≥30 kg/m2 in 46 (40%). Recurrence-free survival (RFS) was 8.8 ± 6.5 and 78.09 ± 12.43 months in the groups with low and high BMI, respectively (p=0.32). Recurrences were found in 7 of 95 (7.4%) receiving Trastuzumab and 13 of 34 patients (38.2%) not receiving. The difference was significant (p<0.001). We detected that 53 patients have a carcinoma insitu on the pathological report (32 patients were BMI<30 kg/ m2 group and 21 patients were BMI ≥ 30 kg/m2 group). Cox regression analysis showed that only presence of carcinoma in situ was significant for PFS, in the population of the study, HR 0.44 (95% CI 1.05-34.28, p=0.044). There was a significant relationship favoring trastuzumab treatment between size of tumor (p=0.04) and hormone receptor positivity with RFS (p =0.002). Moreover, in the hormone receptor negative group, the risk of recurrence was 7.6 folds in the absence of trastuzumab treatment. Median follow-up was 24 months (range 3-257) and recurrence was found in 20 patients (15.5 %). Five patients died during follow-up. Presence of carcinoma-in-situ and use of Trastuzumab had influenced RFS in the population of the study. Rate of hormone receptor negativity was higher and RFS was longer in obese patients than non-obese patients; however, the difference was not significant (p =0.659). Conclusion: Trastuzumab is effective in breast cancer patients to prevent the recurrence, particularly in hormone receptor negative patients. Pam Med J 2013;6(1):5-11
UR  - https://dergipark.org.tr/tr/pub/patd/issue//392780
L1  - https://dergipark.org.tr/tr/download/article-file/422509
ER  -